Reacción a "Both the drug orforglipron and a probiotic supplement help patients with obesity maintain their weight loss, according to two independent clinical trials "

The ATTAIN-MAINTAIN study is a high-quality trial in terms of methodology: a phase 3b, randomised, double-blind, placebo-controlled trial in patients who had previously lost weight with tirzepatide or semaglutide as part of the SURMOUNT-5 study. Its main value lies in answering a highly clinical question: what happens if, following significant weight loss with an injectable treatment, patients switch to an oral option such as orforglipron to maintain the benefit? The results are consistent and clinically relevant: orforglipron enabled a higher proportion of weight loss to be maintained than placebo, following both tirzepatide and semaglutide, with a safety profile dominated by gastrointestinal effects, generally mild or moderate. However, there are significant limitations: it was not compared against continuing semaglutide or tirzepatide; the population was drawn solely from the United States; it was a selected cohort—patients who had already tolerated and responded to incretins; it did not include diabetes; and the follow-up was only one year. Furthermore, the use of orforglipron as rescue therapy in the placebo group partially limits a pure long-term comparison. Overall, the study fits very well with previous evidence showing that obesity is a chronic and relapsing condition, and that discontinuing treatment often leads to weight regain. Its most practical implication is that a sequential strategy—potent injectable treatment to induce weight loss followed by maintenance with an oral GLP-1 receptor agonist—could be a realistic alternative to improve adherence, acceptability and scalability, although it does not yet demonstrate that it is superior to continuing the injectable treatment.

The trial with pasteurised Akkermansia muciniphila MucT also has a sound design: randomised, double-blind and placebo-controlled, with an initial low-calorie diet phase followed by a 24-week maintenance phase. The primary outcome is positive: participants treated with Akkermansia regained less weight than those in the placebo group, with a difference of approximately 2 kg during the maintenance phase, and the effect appeared to be greater in subjects with lower baseline abundance of Akkermansia. Furthermore, the study provides interesting mechanistic data on insulin sensitivity, faecal energy excretion, microbiota and gene expression in adipose tissue, making it biologically plausible rather than merely descriptive. That said, caution is warranted: it is a small, short-term study conducted in a highly selected population and without comparison to current anti-obesity drug treatments. The magnitude of the effect is modest and does not allow us to conclude that this intervention is an alternative to incretin agonists, but rather a possible complementary strategy. Mechanistic questions also remain, as there was no active bacterial comparator or modified strains to allow the effect to be attributed with certainty to specific components of Akkermansia. Therefore, in my view, the study is promising, but it should be interpreted as a clinical and metabolic proof of concept, not as definitive evidence to change clinical practice.